Sengsayadeth Salyka, Savani Bipin N, Oluwole Olalekan, Dholaria Bhagirathbhai
Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center Nashville Tennessee USA.
EJHaem. 2021 Nov 24;3(Suppl 1):6-10. doi: 10.1002/jha2.338. eCollection 2022 Jan.
In recent years, we have seen rapid expansion of chimeric antigen receptor T-cell (CAR-T) therapies in multiple malignancies. CAR-T therapy has profoundly altered the treatment landscape of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and B-cell maturation antigen-directed CAR-T therapies have shown high overall response rate and durable remissions in patients who have failed standard therapies. Multiple studies are underway exploring the role of CAR-T-cell therapy as earlier line of treatment. In high-grade B-cell lymphoma, CD19 CAR-T therapy may replace autologous hematopoietic cell transplantation as second line therapy in near future. CAR-T-cell therapy targeting novel tumor-associated antigens will help expand utility of this treatment modality in other hematological malignancies. It may also help overcome limitations of currently approved CAR-T-cell therapies. In this review, we have provided an overview of currently approved CAR-T therapies and upcoming clinical trials which may potentially impact the clinical practice.
近年来，我们看到嵌合抗原受体T细胞（CAR-T）疗法在多种恶性肿瘤中迅速发展。CAR-T疗法深刻改变了非霍奇金淋巴瘤、B细胞急性淋巴细胞白血病和多发性骨髓瘤的治疗格局。目前可用的靶向CD19和B细胞成熟抗原的CAR-T疗法在标准治疗失败的患者中显示出高总体缓解率和持久缓解。多项研究正在进行中，以探索CAR-T细胞疗法作为早期治疗手段的作用。在高级别B细胞淋巴瘤中，CD19 CAR-T疗法可能在不久的将来取代自体造血细胞移植成为二线治疗方法。靶向新型肿瘤相关抗原的CAR-T细胞疗法将有助于扩大这种治疗方式在其他血液系统恶性肿瘤中的应用。它也可能有助于克服目前已获批的CAR-T细胞疗法的局限性。在这篇综述中，我们概述了目前已获批的CAR-T疗法以及可能对临床实践产生潜在影响的即将开展的临床试验。
